Surgical Instruments & Devices

SHERIDAN, WYOMING – May 7, 2025 – The growing prevalence of rotator cuff tears, coupled with increasing patient expectations, has sparked a reevaluation of traditional surgical approaches. With more than 750,000 rotator cuff repairs performed annually in the U.S. and the number rising steadily, it’s clear that surgical interventions must evolve to meet the challenges of faster recovery times, improved functional outcomes, and better patient satisfaction.

SHERIDAN, WYOMING – May 6, 2025 – Zimmer Biomet Holdings, Inc., a global leader in medical technology, has officially launched the "You’ll Be Back" campaign, led by their Chief Movement Officer, Arnold Schwarzenegger. The campaign aims to support millions of individuals suffering from joint pain by offering a unique online community. This initiative seeks to empower people with the knowledge and resources they need to make informed decisions about their mobility and overall health.

SHERIDAN, WYOMING – May 6, 2025 – Stryker Corporation (NYSE: SYK) has announced its operating results for the first quarter of 2025, showing significant growth in both reported and organic sales, underscoring the company’s strong market performance. The global leader in medical technology posted a notable 11.9% increase in net sales, achieving $5.9 billion, with organic sales growth reaching 10.1%.

SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific Corporation (NYSE: BSX) has reported strong financial results for the first quarter of 2025, driven by sustained product demand, successful execution of its innovation strategy, and solid geographic performance. The company posted net sales of $4.663 billion, reflecting a 20.9% year-over-year increase on a reported basis, exceeding its own guidance range and affirming its leadership position in the global medical device sector.

Double-Digit Revenue Growth Across Segments and Regions

SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific has announced landmark 12-month results from the second phase of its ADVANTAGE AF study, revealing that the FARAPULSE™ Pulsed Field Ablation (PFA) System has successfully met all primary safety and efficacy endpoints in patients with persistent atrial fibrillation (AF). The data, unveiled at the PFA Live Case Summit in San Diego and published in Circulation, mark a strategic leap forward in the treatment of complex cardiac arrhythmias using non-thermal ablation technology.

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has announced encouraging 3-month results from its pivotal Omny-IRE clinical trial, spotlighting the high-performance capabilities of its investigational OMNYPULSE™ Platform.

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has announced the presentation of 22 sponsored or funded clinical studies at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego, showcasing its continued leadership in the electrophysiology space.

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has marked a significant milestone in the evolution of robotic-assisted surgery by completing the first clinical trial cases of its OTTAVA™ Robotic Surgical System. This development positions the company at the forefront of innovation in minimally invasive procedures, reinforcing its strategic commitment to delivering cutting-edge surgical technologies that raise standards in operating rooms worldwide.

Strategic Leap in Robotic-Assisted Surgery

SHERIDAN, WYOMING – May 5, 2025 – Shockwave Medical, Inc., a Johnson & Johnson MedTech company and global leader in circulatory restoration, has officially initiated its FORWARD CAD Investigational Device Exemption (IDE) study. This pivotal research effort will evaluate the safety and efficacy of the Shockwave Javelin Coronary IVL Catheter for the treatment of difficult-to-cross, heavily calcified coronary artery lesions—an area with high unmet clinical need and procedural risk.

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure™ defibrillation lead—the smallest-diameter, catheter-delivered defibrillation lead for right ventricular implantation. This approval marks a major advancement in cardiac rhythm management, offering physicians a less invasive, highly durable solution to treat life-threatening arrhythmias in both adults and adolescents with smaller anatomies.